Quantcast

Latest Glycoproteins Stories

2014-05-07 04:22:16

OXFORD, England and SAN JOSE, May 7, 2014 /PRNewswire/ -- Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that it has obtained the exclusive global rights to certain Xenomouse(R) antibodies generated by Amgen and to ImmunoGen's maytansinoid ADC technology for an undisclosed target. The rights were granted under the existing strategic...

2014-04-24 12:30:09

NEW YORK, April 24, 2014 /PRNewswire-USNewswire/ -- Scientists from The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) have discovered a new vulnerable site on HIV that antibodies can attack to prevent infection from a broad range of the virus' many variants. http://photos.prnewswire.com/prnvar/20131210/DC30761LOGO "HIV has very few known sites of vulnerability, but in this work we've described a new one, and we expect it will be useful in developing a...

2014-04-11 08:24:18

LONDON, April 11, 2014 /PRNewswire/ -- ThioBridge(TM) linker to attach different payloads to a range of antibodies PolyTherics Limited ("PolyTherics"), a provider of technologies and services to enable the development of better biopharmaceuticals, today announced an extension to its ThioBridge(TM) antibody drug conjugate ("ADC") collaboration with MacroGenics Inc (NASDAQ: MGNX), a US biotechnology company developing innovative medicines utilizing its next...

2014-04-10 08:28:53

NEW YORK, April 10, 2014 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM), is an emerging biopharmaceutical company focused on the $54 billion market for cancer drugs. The Company's most advanced products are Actimab(TM)-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia (AML) and Iomab(TM)-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic...

2014-04-08 12:32:32

WASHINGTON, April 8, 2014 /PRNewswire-USNewswire/ -- Though the 11 most popular hospital urine pregnancy tests perform well in the first month after conception, a new study published in Clinical Chemistry, the journal of AACC, reveals the alarming statistic that nine of these tests become significantly more likely to produce false-negative results after the 5(th) to 7(th) week of pregnancy. http://photos.prnewswire.com/prnvar/20130701/PH41045LOGO When a human egg is fertilized,...

2014-04-08 12:26:42

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:2014 Opportunities in the US Endocrine Function Testing MarketThis new 271-page report from Venture Planning Group provides a comprehensive analysis in the US endocrine function market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares and strategic profiles of leading suppliers. The report provides test volume and sales forecasts by country and...

2014-04-07 04:21:25

BREDA, The Netherlands and GHENT, Belgium, April 7, 2014 /PRNewswire/ -- New findings to be presented at the American Association for Cancer Research annual meeting arGEN-X, a clinical stage human therapeutic antibody company, will present data on how its SIMPLE Antibody(TM) platform has identified four 'hotspots' on the MET protein that are suitable for therapeutic antibody targeting. Encoded by the oncogene c-Met, MET...

2014-04-04 08:25:40

NORTHRIDGE, Calif., April 4, 2014 /PRNewswire-USNewswire/ -- A daily dose of S-equol (13.1 mg), delivered via a fermented soy germ-based nutritional supplement to manage menopause symptoms, showed no impact on reproductive or thyroid hormones or the menstrual cycles of premenopausal women, according to a peer-reviewed study reported in a poster at the Academy of Women's Health 2014 annual meeting in Washington, DC. Previous controlled clinical trials documented that daily doses of...

2014-04-03 16:23:53

AUSTIN, Texas, April 3, 2014 /PRNewswire/ -- XBiotech announced today that it acquired the patent estate of Strox Biopharmaceuticals relating to antibody therapies for methicillin resistant staphylococcus aureus (MRSA). XBiotech is developing next generation natural immune therapies to address serious and drug resistant bacterial infections. The in-licensed technology is reportedly intended to expand and strengthen XBiotech's position for its infectious disease product development...

2014-04-03 08:22:27

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/gw6znv/the_engineered ) has announced the addition of the "The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) A Comparative Analysis And Assessment Of TCR Technologies, Pipelines And Companies From An Industry Perspective...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related